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Abstract Complex Regional Pain Syndrome (CRPS) is
associated with non-dermatomal patterns of pain, unusual
movement disorders, and somatovisceral dysfunctions.
These symptoms are viewed by some neurologists and psy-
chiatrists as being psychogenic in origin. Recent evidence,
however, suggests that an autoimmune attack on self-
antigens found in the peripheral and central nervous system
may underlie a number of CRPS symptoms. From both
animal and human studies, evidence is accumulating that
neuroinflammation can spread, either anterograde or retro-
grade, via axonal projections in the CNS, thereby establishing
neuroinflammatory tracks and secondary neuroinflammatory
foci within the neuraxis. These findings suggest that
neuroinflammatory lesions, as well as their associated
functional consequences, should be evaluated during the
differential diagnosis of non-dermatomal pain presentations,
atypical movement disorders, as well as other “medically
unexplained symptoms”, which are often attributed to psy-
chogenic illness.
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Hysteria has its laws, its determination, precisely like a
nervous system ailment with a material lesion. Its ana-
tomical lesion still eludes our means of investigation…”
Dr. Jean-Martin Charcot, 1890.
Introduction
Complex Regional Pain Syndrome (CRPS), formerly referred
to as Reflex Sympathetic Dystrophy (RSD), is one of the
diseases classically defined as hysteria minor by the early
neurologist, Dr. Jean-Martin Charcot (1892). To this day, the
sensory disorders and movement disorders of CRPS are some-
times diagnosed as somatization disorders, or conversion dis-
orders, respectively (Ochoa and Verdugo 1995; Verdugo and
Ochoa 2000; Hawley and Weiner 2011). Such somatoform
disorders are defined as a chronic condition where physical
symptoms are observed, but no physical cause can be found
(Stone et al. 2011). In the absence of medical explanations for
the symptoms, a psychological etiology is presumed (Stone et
al. 2009, Stone et al. 2010).
In contrast to these views, substantial evidence has been
obtained that CRPS is a neuroinflammatory disorder, with a
probable autoimmune component inmany individuals (Blaes et
al. 2007, Goebel et al. 2011; Kohr et al. 2011; Goebel 2011). In
a study of adult CRPS patients, 90% of the cohort had autoanti-
bodies to either the beta(2)-adrenergic receptor (β2AR) or the
muscarinic acetylcholine receptor (M2R) (Kohr et al. 2011).
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55% of the patients had autoantibodies to both neurotransmitter
receptors. Integrating these new research findings into neuro-
logical and psychiatric practice will require a comparison be-
tween historical views on hysteria, contemporary views on
psychogenic illness, as well as emerging information about
neuroautoimmunity and neuroinflammation.
In the 1880s, Charcot first hypothesized that hysteria was
generated by non-structural lesions in the nervous system
(Harris 2005). He postulated that these lesions were likely to be
biochemical or physiological in character. In describing a case
study, during a lecture on hysteria, Charcot (1885) stated: “We
have here unquestionably one of those lesions which escape our
present means of anatomical investigation, and which, for want
of a better term, we designate dynamic or functional lesions.”
Charcot’s concepts of dynamic and functional lesions are
especially useful to utilize when analyzing the local and non-
local effects of neuroinflammation within the nervous system.
Neuroinflammation is now implicated in many neurological
and neuropsychiatric disorders that were once classified as
hysteria, e.g. dystonia (Sigel et al. 2007; Lee et al. 2009;
Simonyan et al. 2010), CRPS (Del Valle et al. 2009), temporal
lobe epilepsy (Huberfeld et al. 2007). In this paper, we discuss
how neuroinflammatory lesions, together with their functional
consequences, are likely to be a subset of the functional and
dynamic lesions that were originally postulated by Charcot to
explain the etiology of hysteria (1885). In addition, we discuss
the need to improve neuroimaging of neuroinflammatory
lesions, to help facilitate the diagnosis and mechanistic under-
standing of neuroinflammation-mediated neurological and
neuropsychiatric disorders.
Physiological versus psychogenic symptoms
In a recent editorial on a paper dealing with medically unex-
plained movement disorders, Stone and Edwards (2011) make
the following comment:
Proving that a symptom affecting a heterogeneous group
of people is “psychogenic” using epidemiological data
may be as unachievable as trying to prove that it is not.
The word psychogenic itself suggests an exclusion of
biological factors that is at odds with a biopsychosocial
model now prevalent in understanding most mental
health disorders and physical symptom syndromes. The
use of this term (i.e. psychogenic) may play a role in
restricting research scope, and also may adversely affect
clinical interest, care, and understanding of these patients.
Studies such as this are helpful in challenging stereo-
types, and may push us away from a narrow dogmatic
approach and toward a broader view of the etiologies and
mechanisms of these common and disabling disorders.
In this context, we discuss a number of questions
related to CRPS and neuroinflammation. Specifically,
does neuroinflammation underlie many of the sensory,
autonomic, and movement disorders of CRPS? If so,
why have these dysfunctions so often been interpreted
as being psychogenic? What diagnostic and mechanistic
criteria are being used to make these conclusions? Are
the diagnostic criteria for psychogenic illness compatible
with emerging views of neuroinflammation and neuro-
autoimmunity? In the following sections, we discuss
how autoimmunity and neuroinflammation may combine
to produce some of the most controversial symptoms in
neurology and psychiatry: the co-morbidities of CRPS.
Neuroautoimmunity and the initiation of CRPS
Recent discoveries have helped to elucidate possible mech-
anisms for the initiation and progression of CRPS. In gen-
eral, neuroautoimmune responses are determined by how
infiltrating leukocytes react to autoantibodies, which bind
to autoantigens located on the surfaces of neuronal and glial
cell targets (Fig. 1). For a substantial fraction of adult CRPS
cases (Kohr et al. 2011), initiation of CRPS may lie in a
breakdown of immunologic self-tolerance, and the develop-
ment of autoantibodies to the β2AR and M2R neurotrans-
mitter receptors. Once autoantibodies have been generated
to these neuroantigens in a given individual, an ongoing
progression of stereotyped autoimmune-mediated neuroin-
flammatory responses might become initiated.
Fig. 1 Potential autoantibody binding sites in CRPS patients for β2AR
(beta(2)-adrenergic receptor) and M2R (muscarinic 2 acetylcholine re-
ceptor) autoautoantibodies. (images modified from The Inner Man™,
Medical Illustrations Company LLC). a. β2AR and M2R sites in the
central nervous system and heart:β2AR in cerebellum—(Reznikoff et al.
1986); β2AR in reticular formation—(Culmsee 2009); β2AR in sympa-
thetic autonomic nervous system—(Katzung 2001), M2R in parasympa-
thetic autonomic system and heart—(Katzung 2001) β2AR also in
astrocytes and microglia (Mantyh et al. 1995; Wang et al. 2010) b.
M2R distribution in pyramidal motor pathway to skeletal muscles M2R
in motor cortex and thalamus—(Levey et al. 1991) M2R in peripheral
nerves—(Katzung 2001)
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Achieving a cellular and molecular understanding of the
clinical progression of CRPS, as well as the generation of its
complex symptoms, requires modeling of the immunologic
and integrative physiology involved. It is important to con-
sider how distressed neurons and glial cells release factors
that stimulate the extravasation of leukocytes and autoanti-
bodies, from the bloodstream, into the parenchyma of the
CNS (Watkins et al. 2007). Serious neuroinflammatory con-
sequences would be expected to arise when β2AR and M2R
autoantibodies exudate from blood vessels, together with
complement proteins and leukocytes (Figs. 1 and 2).
Beggs et al. (2010) have recently found that the blood–brain
barrier in the spinal cord of rats is transiently compromised in
response to peripheral nerve injury. Extravasation of leukocytes
into the parenchyma of the cord has been found to last for
several days following a sciatic nerve injury (Milligan ED,
personal communication). In a CRPS patient with a peripheral
nerve injury, one might expect circulating autoantibodies to
exudate into the parenchyma of the injured nerve. Autoimmune
attack on peripheral nerves might trigger leukocyte extravasa-
tion, autoantibody exudation, and neuroimmune activation in
the spinal cord as well. Neuroinflammation in the cord could
produce a mixture of pain, autonomic dysfunctions, somato-
visceral dysfunctions, and/or abnormal motor functions. CRPS
is a neurological disorder where many of these dysfunctions
can be expressed in a single patient (Schwartzman et al. 2009).
Vascular breakdown or leakage may be a critical step in
allowing autoantibodies access to the neuroautoantigens of
CRPS patients. Focal accumulations of neuroautoantibodies
on target cells are likely to initiate neuroinflammatory
responses. Whether the antibody-initiated neuroinflamma-
tion remains as discrete foci, or whether the neuroinflam-
mation begins to propagate through the neuraxis, are key
questions for understanding the chronicity and spread of
CRPS symptoms in a given patient. CRPS shows distinctive
patterns of spread throughout the body (van Hilten et al.
2001; van Rijn et al. 2011). Spread of CRPS symptoms to
other body sites often occurs in a contiguous fashion. How-
ever, it is possible for CRPS symptoms to appear quickly in
non-contiguous locations (van Hilten et al. 2001). Both
types of CRPS spreading behavior could be linked to the
establishment and spread of neuroinflammation within the
neuraxis. At this point in time, how CRPS symptoms spread
within the neuraxis is primarily known from an analysis at
the symptom level. Cellular and molecular knowledge about
the spread of neuroinflammation within the neuraxis in other
disorders comes from the neuroimaging of human patients,
as well as from animal model studies of neuropathic pain.
Spreading neuroinflammation
Numerous studies have revealed that neuroinflammation does
not always remain confined to specific foci in the CNS.
Cascades of intercellular signaling allow neuroinflammation
to migrate either anterograde or retrograde from primary sites
of neuroinflammation.
Banati et al. (2001) utilized radiolabeled PK11195 as a
biomarker to image spreading neuroinflammation in the
CNS in response to peripheral nerve injury. They deter-
mined that peripheral nerve injury frequently leads to micro-
glial activation at the first order synapse of injured neurons.
In a minority of cases, neuroinflammation migrated trans-
synaptically to the second order synapse, located in higher
levels of the CNS, such as the thalamus. Banati (2002) also
postulated that by altering neurotransmission and the coding
of neuroinformation, neuroinflammation at the first and
second order synapses could become drivers for higher-
order functional changes within the nervous system.
In concise terms, Banati’s principles are:
a. Neuroinflammation can spread to second order synapses
via remote neuroimmune activation.
b. Neuroinflammation may be the physiological driver for
functional pathologies at third order synapses, as well as
higher-order integrative processes (Banati 2003).
Hereafter, we refer to paths of spreading neuroinflamma-
tion in the CNS as neuroinflammatory tracks (Fig. 2). This
term refers to discrete pathways of neuroinflammation that
involve anatomical linkage between primary and secondary
foci of neuroinflammation.
The ontogeny of posttraumatic neuroinflammatory tracks
was first documented in rodents by Banati et al. (1997).
Later, Banati et al. (2001) determined that a cohort of
chronic pain patients, who had suffered an antecedent pe-
ripheral nerve injury, exhibited persistent microglial activa-
tion in their contralateral thalamus. Banati et al. (2001)
proposed that neuroinflammation had migrated from first
order synapses in the spinal cord in these patients, to second
order nociceptive synapses, which are located within the
contralateral thalamus. Banati (2003) have also obtained
evidence for remote neuroimmune activation (also referred
to as transsynaptic microglial activation) in a number of
neurological disorders.
Saab and Hains (2009) have discussed cellular and
molecular mechanisms for such remote neuroimmune
activation. Release of the cytokine CCL21 from the terminal
of first order nociceptive neurons is capable of initiating
secondary sites of neuroinflammation where the noci-
ceptive neurons terminate, such as the VPL nucleus of
the thalamus. Saab and Hains (2009) have postulated
the neuroinflammation in the thalamus drives dysrhyth-
mias in thalamocortical loops, which can be detected using
EEG (Saab, 2012), thus producing a central generator for
neuropathic pain.
Neuroautoantibodies in CRPS patients could modify,
exaggerate, and sustain this type of remote neuroimmune
454 J Neuroimmune Pharmacol (2013) 8:452–469
activation (Fig. 1). In this regard, remote neuroimmune
activation via neuronal projections may account for the
spread of microglial and astroglial activation within the
spinal cord of CRPS patients (Del Valle et al. 2009; van
Rijn et al. 2011). It has also been hypothesized that spinal
neuroinflammation could spread to supraspinal sites in
CRPS patients via remote neuroimmune activation to
initiate movement disorders (Cooper and Przebinda 2011;
Cooper 2011b).
Neuroinflammation and central sensitization
The term “central sensitization” is often used to describe
changes in the central nervous system associated with the
establishment and progression of the neuroinflammatory
diseases. In an experimental model of peripheral inflamma-
tory pain (Roberts et al. 2009), neuroinflammation spreads
from the first order synapse, located in the spinal cord, to a
second-order synapse in the rostroventromedial medulla
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(RVM). Sensitization of first order and second order trigemi-
nothalamic neurons, for instance, may contribute to the on-
togeny of migraine (Borsook et al. 2006; Noseda et al.2011).
Non-dermatomal patterns of pain can be generated by neuro-
inflammation within the thalamus (Burstein et al. 2010).
In CRPS patients, features of central sensitization appear
to involve a complex set of neuroinflammatory responses
involving NMDA receptors, glial cell activation in the spi-
nal cord (Kiefer et al. 2008; Del Valle et al. 2009), as well as
the release of pro-inflammatory cytokines from neurons,
glia (Munts et al. 2008), and leukocytes (Alexander et al.
2012).
Extravasation of leukocytes and exudation of autoanti-
bodies into the parenchyma of the nervous system are key
features of central sensitization during a neuroautoimmune
attack of the CNS. The autoimmune attack is focused on
sites where autoantibodies bind. Autoimmune attack can
potentially lead to the loss of GABAergic inhibitory interneur-
ons (e.g. Stiff-person Syndrome) (Rokocevic and Floeter
2012). In addition, BDNF released from endothelial cells
(Bayas et al. 2002) or activated microglia in a neuro-
inflammatory site (Trang et al. 2012) can produce a down-
regulation of the potassium-chloride co-transporter, KCC2
(Blaesse et al. 2009; Trang et al. 2012), which plays a critical
role is maintaining transmembrane chloride gradients in CNS
neurons.
Reduction of the transmembrane chloride gradient in the
post-synaptic neuron leads to conversion of inhibitory tone
to excitatory tone (asterisks in Fig. 2). KCC2 downregulation
appears to help BDNF promote neuronal survival (Huberfeld
et al. 2007). By converting GABAergic and glycinergic syn-
apses to excitatory function, BDNF promotes increased Ca2+
influx into the affected neurons. Although these dynamics
may help neuronal survival (Huberfeld et al. 2007), the result-
ing synaptic conversion can potentially provoke major dis-
ruptions in the logic of neural circuits, leading to major
dysfunctions in sensory, motor, and autonomic processes
(Cooper and Przebinda 2011) (Fig. 2).
Major nerve injuries in rodents and humans are known to
result in leukocyte infiltration into the PNS and CNS (Stoll
and Bendszus 2010). Exudation of autoantibodies into the
parenchyma of basal ganglia is hypothesized to initiate
neuroinflammation and movement disorders (Ahlskog et
al. 2001; Citak et al. 2004). Peripheral nerves injury can
result in a transient breakdown of the blood-spinal cord
barrier and the blood–brain barrier (Beggs et al. 2010).
The transient breakdowns in these barriers can be blocked
by local anesthesia, indicating that the transient increase in
capillary permeability in the CNS is dependent on peripheral
nerve activity.
Do minor peripheral nerve injuries in CRPS patients
trigger the extravasation of leukocytes and the exudation
of autoantibodies from blood vessels, leading to the initia-
tion of persistent sites of neuroinflammation in the PNS,
autonomic nervous system, and CNS? Later in this paper,
we discuss whether modern neuroimaging methods will be
able to answer this question.
CRPS movement disorders
CRPS researchers have utilized symptomatology to create
validated diagnostic criteria for CRPS (Harden et al. 2010).
Using a set of four major symptom categories (amplified
pain, autonomic dysfunction, motor dysfunction, sudomo-
tor/trophic changes), a set of diagnostic criteria has been
identified, which is both sensitive and specific to identify
CRPS (Harden 2010). The movement disorders associated
with CRPS include fixed dystonia, myoclonus, and tremors.
Approximately 80% of CRPS patients have paresis in their
affected body limbs (Birklein et al. 2000).
The nosological effort to define the movement disorders
of CRPS as being either physiologic (organic) or psychogenic
(non-organic) has been long and controversial (Reedijk et al.
Fig. 2 A conceptual model for functional pathophysiologies arising
from neuroinflammatory tracks. Neuroinflammation leads to a loss of
sensory gating, as well as excessive gain, in sensorimotor pathways. a.
Normal sensory processing (dotted lines). GABAergic interneurons
provide inhibitory tone at both first order and second order synapses.
Non-activated microglia (M) lie in the CNS parenchyma. Leukocytes
(L) and autoantibodies are present in the CNS vasculature. b. Periph-
eral injury initiates anterograde central sensitization. Microglial acti-
vation takes place in response to cytokines released at the terminals of
injured primary afferents (first order synapse). Breakdown of the
blood–brain barrier (or the blood-spinal cord barrier) allows activated
leukocytes and autoantibodies to extravasate into the parenchyma of
the CNS, leading to autoimmune mediated neuroinflammation. Release
of Brain-Derived Neurotrophic Factor (BDNF) from plasma, endothe-
lial cells, and activated microglia alter chloride homeostasis in post-
synaptic neurons. Accumulation of intracellular chloride (yellow)
results in synaptic conversion, changing GABAergic and glycinergic
synapses from inhibitory tone to excitatory tone (Huberfeld et al. 2007;
Price et al. 2009; Cooper and Przebinda 2011). Sensory gating is lost at
the first order synapse. Graded sensory transmission is lost within the
neural circuit. Upregulation (red) of excitatory transducers (e.g. gluta-
mate receptors) results an increase in excitatory tone. Functional
changes in the circuit result in a collapse of feedforward inhibition
and filtering at the first-order synapse (pain gate in the nociceptive
circuit) (Cooper and Przebinda 2011). Neuroimmune activation
spreads to the second order synapse through the release of the cytokine
CCL21 from the terminals of first order neurons (Saab and Hains
2009). Small sensory stimuli provoke large (thick dotted arrows)
volleys in second order neurons. c. Central injury to the CNS can
result in retrograde central sensitization via neuroimmune activation.
Loss of inhibitory interneurons (grey outlines), either by autoimmune
attack (e.g. Stiff-Person Syndrome) (Sandbrink et al. 2003; Rokocevic
and Floeter 2012), or by metabolic crisis (e.g. hypoglycemia, hypoxia,
or excitotoxicity), permanently reduces inhibitory tone in the sensori-
motor circuit. These conditions, and/or the conditions illustrated in
panel B, may contribute to post-traumatic dystonias, non-dermatomal
pain distributions, autonomic, and/or somatovisceral disorders, in
patients with autoimmune-mediated neuroinflammation, even after
the initial neuroinflammatory event subsides
R
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2008; Munts and Koehler 2010). Recently, a group of move-
ment disorder specialists, who have studied fixed dystonia in
CRPS patients, have stated:
“Traditional medical dualism polarizes opinion as to
whether fixed dystonia is best characterized as a psy-
chogenic or an organic disorder.…On the basis of our
cases and previous data with regard to amputation in
complex regional pain syndrome type I (CRPSI), we
speculate that fixed dystonia is itself part of the spectrum
of body integrity identity disorders.”
Toward the end of their paper, Edwards et al. (2011)
state:
“The theory outlined above generates some testable
hypotheses regarding the pathophysiology of fixed
dystonia that attempt to move beyond the dualistic
battle between classifying these patients as organic or
psychogenic toward a more integrated view of brain
dysfunction in this enigmatic disorder.”
This statement represents a major conceptual shift in the
differential diagnosis of fixed dystonia. The statement sug-
gests that the fixed dystonias should be reanalyzed in terms
of observable neuropathologies. Indeed, distortion of the
body schema has been detected in CRPS patients using
fMRI (Maihöfner et al. 2003, 2004, 2007). Deficient drive
from the parietal cortex to the supplementary cortex and
motor cortex is also detected (Maihöfner et al. 2007), lead-
ing to “neglect-like” motor symptoms (Galer et al. 1995;
Kolb et al. 2012).
Psychogenic was originally coined to indicate non-
organic phenomena “originating in the mind” (Lewis
1972). Using the original semantic of the term “psychogenic”,
it is difficult to interpret distortions of somatosensory maps in
CRPS patients as evidence for psychogenic disease. Evidence
for body schema distortions, for instance, has been detected in
patients with low back pain (Bray and Moseley 2011). Wide-
spread allodynia can be produced in rodent models by induc-
ing extensive neuroinflammation within the thalamus
(Burstein et al. 2010). Thus, non-dermatomal pain distribu-
tions, or distortions of the body schema in the somatosensory
cortex, cannot be used as positive diagnostic evidence for
psychogenic illness. Body schema distortion or thalamic
neuroinflammation provide physiological alternatives to the
differential diagnosis.
The need of obtaining an accurate differential diag-
nosis for a disorder is different from the goal (and/or
timescale) of obtaining a mechanistic explanation for a
disorder. As a consequence, the clinical goals for obtaining a
differential diagnosis of a disease state, versus obtaining a
mechanistic explanation for the disease state, should not be
conflated. In the absence of positive diagnostic evidence for a
presumed etiology, the term “idiopathic” should be employed
for the symptom, rather than “medically unexplained symp-
tom.” This later term biases differential diagnosis towards the
unwarranted conclusion of psychogenic illness. From a noso-
logical perspective, it is unclear whether movement disorders
that are linked to neuroinflammation should be classified
as organic movement disorders, functional movements disor-
ders, or both.
Re-conceptualizing CRPS symptoms
Can the symptoms of CRPS be re-classified in terms of
mechanism/processes, rather than presumed etiology?
Without a complete knowledge of how symptoms de-
velop with time, perhaps it is most effective to elucidate
whether specific physiological states are present in a
given patient. In terms of evaluating neuroautoimmune
mechanisms for CRPS symptoms, it is useful to consid-
er five interconnected processes: (a) autoimmune sero-
conversion, (b) amplification of autoimmune cells and
autoantibodies, (c) autoimmune attack, (d) neuroimmune
activation, and (e) functional and structural disruption of
neural networks.
CRPS symptoms might be categorized by using one or
more of the following mechanistic processes and concepts,
which could result in the type of lesions indicated:
– Infiltration of autoantibodies into nervous tissues (func-
tional lesion)
– Infiltration of leukocytes into nervous tissues (structural/
functional lesion)
– Focal sites of cytokine imbalance (functional/dynamic
lesion)
– Remote neuroimmune activation of glia (structural/
functional lesion)
– Breakdown of blood brain barrier (structural lesion)
– Loss of inhibitory tone (functional lesion)
– Excessive loop gain in neural circuits (dynamic lesion)
– Thalamic neuroinflammation (structural/functional
lesion)
– Loss of sensory gating (functional lesion)
– Synaptic conversion (functional lesion)
– Thalamocortical dysrhythmias (dynamic lesion)
– Distortion of a somatotopic map (structural/functional
lesion)
– Altered connectivity within the brain (dynamic/functional
lesion)
By utilizing the concepts of neuroinflammatory lesions,
dynamic lesions, and functional lesions, the differential
diagnosis focus shifts away from establishing a psychogenic
versus physiologic etiology for a given symptom, toward a
more mechanistic analysis of the multiple functional and
structural pathologies that are common in CRPS patients.
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Linking neuroautoimmunity with sensorimotor dysfunction
Neuroinflammation provides a wide range of mechanisms to
alter sensorimotor function. A recent publication describes a
form of chorea in three individuals with nonketotic hyper-
glycemia (Wang et al. 2009). The authors hypothesize that
circulating autoantibodies enter the parenchyma of the basal
ganglia as a consequence of hyperglycemia shock to the
microvasculature, resulting in a breakdown of the local
brain-brain barrier. Microvascular lesions in the basal gan-
glia were detected with MRI and gadolinium contrast. In
one patient the lesion expanded from the right globus pal-
lidus to include the right putamen (Wang et al. 2009):
“These results, together with distinctive distribution of
the lesions affecting the putamen, globus pallidus and
the head of the caudate without involving the anterior
limb of internal capsule, suggest that the autoimmune-
mediated inflammatory process against basal ganglia
neurons may take part in the pathogenesis of some
patients with NKH (nonketotic hypoglycemia) induced
HC–HB (hemichorea-hemiballism). Conceivably, the
basal ganglia might be susceptible to autoimmune attack
by anti-GAD65 or other autoantibodies via opening of
the blood–brain barrier by hyperglycemia-related
hyperosmolality.”
The movement disorders in these patients might also be
caused by immune complexes activating microglia in the
basal ganglia to produce pro-inflammatory cytokines, which
in turn induce neuronal dysfunction.
The authors hypothesize that neuroinflammation in these
patients results from vascular lesions. Localized breakdown of
the blood–brain barrier allows autoantibodies to infiltrate into
the parenchyma of the basal ganglia. In this context, the
neurovascular lesion is both an organic lesion, as well as a
functional lesion. Structural features of the neurovascular
lesion are often visible by MRI. Functional changes produced
by the neurovascular lesion are evident in the development of
the movement disorder. In this case, the neurophysiological
mechanisms bywhich autoimmune-mediated neuroinflamma-
tion in the basal ganglia creates the functional pathology (i.e.
hemichorea) remain unknown. Microvascular lesions in the
brain and spinal cord may be a common way for individuals
with neuroautoimmune disorders to have transient neurolog-
ical and neuropsychiatric events, including movement disor-
ders (Mayer et al. 2010).
The above case illustrates the inherent difficulty of using
“medically unexplained symptoms” as a positive diagnostic
term. In the previous example, positive radiological evi-
dence provides a plausible etiology of the movement disor-
der, as well as a positive explanation for the positive
response to pharmacological intervention. However, what
would the clinical diagnosis be if MRI were not available,
and an actual neurovascular lesion were not visible with X-
ray or CT? In the absence of evidence for such structural
changes, a practitioner applying the DSM-IV diagnostic
criteria could easily misdiagnose the patient as having a
motor conversion disorder. Thus, the clinical diagnosis, as
well as the subsequent treatment scheme, hinges on the
inherent instrumental sensitivity (sometimes marginal) of
the neuroimaging modality used to detect neurovascular
disruption.
Autoimmunity and movement disorders
Neurologists and psychiatrists have commented that certain
individuals appear to be pre-disposed to certain disorders.
Some of these individuals may have autoimmune disorders
(Appenzeller et al. 2011; Vincent et al. 2011; Irani and
Vincent 2011). Unusual tardive movement disorders might
occur in individuals with autoimmunity. The following
study is illustrative.
A cohort of female patients with antiphospholipid anti-
bodies who took oral contraceptive drugs developed chorea
(Cervera et al. 1997). The chorea ceased once the medica-
tion was discontinued. The authors of this paper concluded
that the unique combination of antiphospholipid (aPL) anti-
bodies and oral contraceptives in these patients produced a
movement disorder. The authors hypothesized that chorea
arose because of changes in blood flow and metabolism in
the basal ganglia, produced by the entrance of autoantibod-
ies into the parenchyma of the basal ganglia. This hypoth-
esis of a neuroautoimmune-mediated metabolic disturbance
fits well with the functional lesion concept, originally pos-
ited by Charcot (1885) to explain the etiological origins of
“hysteria.”
Instead of autoimmune-mediated neuroinflammation, the
term “medically unexplained symptoms” has often been used
to describe sensory, autonomic, and motor symptoms of
CRPS patients, even though there is an extensive literature
describing neurophysiological pathologies andmechanisms in
these patients. There are several inherent difficulties with the
psychogenic hypothesis. However, absence of evidence is not
evidence of absence. In addition, characteristics such as the
speed of onset and remission have also been used to assign
symptoms to neurological vs. psychogenic causes, with the
assumption that neurological disease processes have a longer
timecourse than psychogenic ones. In this regard, rapid onset
and rapid remission have often been used as criteria for
diagnosing psychogenic movement disorders, even though
autoimmune disorders are well know for their cyclic character
of remission and relapse.
Another salient difficulty in psychogenic hypotheses is
that they often conflate a cluster of atypical symptoms with
a psychological pathology. This reasoning excludes atypical
presentations of physiological processes, including
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neuroinflammation and neuroautoimmunity, from the differ-
ential diagnosis. A patient may have an atypical genetic
background, leading to atypical symptoms. Alternatively, the
person may have a latent immune response to an infectious
agent (Söderberg–Nauclér 2012). Or the person may have
been placed on a medication that is counter-indicative for a
nervous system with focal sites of neuroinflammation, result-
ing in anomalous motor or sensory phenomena. In addition,
prior injuries, surgeries, infectious antigen presentations, or
autoantibody production may have ‘primed’ the neuroim-
mune system for an exaggerated neuroimmune response
(Hains et al. 2010; Frank et al. 2012). Any or all of the above
conditions may exist in certain CRPS patients. These alterna-
tive etiologies should be considered before assigning a puta-
tive psychogenic etiology to any particular symptom. Self-
limiting chorea, for instance, has been associated with Parvo-
virus B19 infection in children (Fong and de Sousa 2006;
Grillo and da Silva 2009). In these cases, immune-mediated
encephalopathies are thought to underlie the chorea, even
though the MRI is unremarkable in these patients (Grillo
and da Silva 2009).
In the diagnosis of CRPS, symptoms such as fixed dys-
tonia are often considered to be a “conversion disorder”
(Verdugo and Ochoa, 1995, 2000; Hawley and Weiner
2011). Rather than being a conversion disorder of a psycho-
logical origin, these fixed dystonic postures may be the
functional consequences of a “seroconversion” event, with
autoantibodies serving as the initiators of neurological and
neuropsychiatric symptoms. Thus, the autoimmune re-
sponse itself may have been induced by a combination of
physical trauma(s) and hormonal changes associated with
psychological stressors, perhaps the onset of symptoms
themselves, which further enhance the autoimmune re-
sponse and symptom severity.
Health professionals have often described physical trau-
ma as antecedent events for CRPS, since the condition was
first described (Mitchell 1872). However, the role for psy-
chological stressors as an initiator of CRPS, rather than a
consequence of the disorder, has not yet been substantiated
(de Rooij et al. 2010).
Individuals with CPRS have often been viewed as having a
pre-existing susceptibility for exaggerated pain andmovement
disorders. If true, where does the predisposition originate?
One possibility is that this predisposition is related to the
presence of autoantibodies to β2AR and M2R. Neuroautoan-
tibodies, for instance, have been found to be associated with
Sydenham’s chorea (Pavone et al. 2006; Brilot et al. 2011),
Sjögren's Syndrome (Vincent et al. 2011), as well certain cases
of Tourette’s Syndrome (Müller et al. 2004; Morer et al. 2008;
Dehning et al. 2009). CRPS may have a similar etiology.
Autoantibodies have been shown to be of creating mul-
tiple pathologies within the body (e.g. Sjögren's Syndrome).
Memory B-cells, and the autoantibodies that they produce,
could be the encoded memory of an earlier traumatic event.
Autoantibodies can be generated from immune responses to
neoplasms (Vincent et al. 2011). The key concept here is
that the development of autoimmunity to specific neuro-
autoantigens may be the initiating event for many cases of
CRPS. Psychological stressors, physical trauma, infectious
agents, and/or genetic susceptibility could all play a role in
the breakdown of self-tolerance, and the onset of an auto-
immune response. This set of etiological linkages fits well
with documented clinical experience with CRPS (Mitchell
1872; Birklein et al. 2000). Psychological stressors and
immunologic priming have been linked to the enhanced
activation of microglia to nervous system injury (Frank et
al. 2007; Hains et al. 2010).
Imaging neuroinflammation in movement disorder patients
Autoimmune-mediated movement disorders are thought to
occur in a number of autoimmune disorders, such as Sjögren’s
Syndrome (van den Berg et al. 1999; Venegas et al. 2005;
Papageorgiou et al. 2007; Min and Youn 2009), Sydenham's
chorea (Vincent et al. 2011), and certain cases of Tourette’s
Syndrome (Morer et al. 2008; Dehning et al. 2009). Method-
ologies currently exist that may provide clinically useful
means to image neuroinflammation in these and other disor-
ders. Using such methods, neuroinflammation might be
expected to be found using PET or MR spectroscopy in the
basal ganglia of aPL patients, and in these and other neural
fields in Sjögren's Syndrome, Sydenham's chorea, and Tour-
ette’s Syndrome, among others. It also would be expected that
the degree of symptoms, such as tics or chorea, would corre-
late with the degree of neuroinflammation.
What happens if the predictive biomarkers are “functional
changes” in the nervous system? Neuroimaging and neuro-
visualization methods are now providing such functional
biomarkers to identify neurophysiologic disorders. Changes
in blood flow in the brain are commonly used to dis-
tinguish alterations of connectivity within the brain. In
certain cases, regional changes in brain metabolism can
be correlated with transient movement disorders (e.g. onset
of paroxysmal or itcal dystonias) (Joo et al. 2004; Yoon
et al. 2007).
The issue of sensitivity is central to the clinical tractability
of using neuroimaging methods to discern the effects of
neuroinflammation in movement disorders. In the case of
immune-mediated movement disorders, Citak et al. (2004)
have commented:
… in our patients with tics, there were no abnormal-
ities on CT or MRI. On the other hand, similar to the
patients with Sydenham’s chorea, our patients with
post-streptococcal tic disorder also showed striatal
hypoperfusion in their SPECT images. This might be
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due to the fact that structural imaging studies might
not be as sensitive as functional imaging studies for
detecting the abnormalities in striatum in Sydenham’s
chorea and tic disorders.
The difficulty in detecting certain neuroinflammatory
lesions in the brain using structural MRI is also illustrated
in the following case study (Maeda et al 2010). A diabetic
man exhibited a transient hemiballism (lasting 4 days) in his
right arm, which was linked to a hypoglycemic crisis. The
movement disorder remitted in response to glucose stabili-
zation with insulin, as well as hemodialysis. Death occurred
two months after the transient hemiballism, from severe
autonomic neuropathy and cardiac arrest. After autopsy,
immunohistological analysis revealed activated microglia
in the man’s left subthalamic nucleus (STN). Within the
same STN, no evidence of neurodegeneration or activated
astroglia was found. It is not clear whether activated micro-
glia played a causative role in the movement disorder.
Microglial activation was present in the STN, while the
hemiballism was in remission. This illustrates that activated
microglia alone cannot explain the transient hemiballism in
this patient. However, the presence of activated microglia in
the STN contralateral to the affected limb does suggest that
a physiological event did occur in the STN, perhaps leading
to a persistent activation of microglial in the affected STN.
Notably, the patient’s brain MRI remained unremarkable
during these transitions (Maeda et al. 2010).
This above case study strongly supports Charcot’s pre-
diction (1885) that dynamic and functional lesions in the
CNS could serve as drivers for movement disorders. In the
above case of hemiballism, the patient apparently suffered
from a functional lesion that had a neuroinflammatory com-
ponent, without appreciable neuronal death within the STN.
However, the neuroinflammatory, functional lesion could
not be visualized using standard MR imaging techniques
(Maeda et al. 2010).
Cell death within the CNS is, of course, a possible
outcome of hyperglycemic or hypoglycemic shock. Neuro-
nal cell death may explain why some patients do not expe-
rience resolution of their chorea after their metabolism is
normalized (Ahlskog et al. 2001, as irreparable damage may
have already occurred (Shan et al. 1998). Loss of inhibitory
interneurons from autoimmune attack (Rokocevic and Flo-
eter 2012) can contribute to excessive excitability in the
excitatory neuron population of deep brain nuclei. This
potential outcome to injury and/or neuroinflammation is
illustrated is Fig. 2c. Autoimmune-mediated movement
disorders are thought to occur in a number of autoim-
mune disorders, such as Sjögren's Syndrome (van den
Berg et al. 1999; Venegas et al. 2005; Min and Youn 2009),
Sydenham's chorea (Vincent et al. 2011), and certain cases of
Tourette’s Syndrome (Morer et al. 2008; Dehning et al. 2009).
Neuroinflammation and movement disorders
Movement disorders occur in a number of disorders that
include neuroautoimmune components, such as Sjögren's
Syndrome (van den Berg et al. 1999; Venegas et al. 2005;
Min and Youn 2009; Alonso-Navarro et al. 2009), Syden-
ham’s chorea (Brilot et al. 2011; Pavone et al. 2006), and
certain cases of Tourette’s Syndrome (Morer et al. 2008).
Autoimmune-mediated neuroinflammation of the basal gan-
glia is suspected in many of these cases.
Besides autoimmune-mediated movement disorders, pe-
ripheral trauma has long been known to be an antecedent of
certain movement disorders (Mitchell 1872; Sankhla et al.
1998; van Rooijen et al. 2011). Mitchell (1872) was among
the first to recognize a linkage between neuroinflammation
and the genesis of movement disorders in CRPS. Although
evidence linking neuroinflammation and movement disor-
ders is rapidly accumulating (van de Warrenburg et al. 2007;
Simonyan et al. 2010; van Rooijen et al. 2011), it is clear
that a complementary set of neuroimaging methods will be
needed to visualize the cellular players and metabolism of
neuroinflammatory lesions, to determine their putative roles
in motor dysfunction. Neuroinflammatory lesions are clearly
heterogeneous in their cellular dynamics, their metabolism, as
well as their chronicity.
An idiopathic case of hyperekplexia (startle syndrome) is
instructive in this regard (van de Warrenburg et al. 2007). A
55-year-old woman initially presented with a stiff neck, as
well as retching when she placed a toothbrush into her
mouth. These symptoms resolved over a period of two
months. The patient subsequently developed bilateral jaw
aches when chewing food. This was followed by severe
involuntary mouth closure on attempts to eat. Two months
later, she noticed that her arms and shoulders would jerk in
response to unexpected sounds or on touching her face. One
month later, her left arm became stiff and tended to assume
abnormal postures. Her gait became more effortful and she
tended to veer to the left.
The patient developed upper and lower extremities jerks,
as well as trismus. In addition, the patient developed ptosis
on the right side. Decreased pinprick sensation around the
nose, upper and lower lip, and forehead; tight and overactive
masseter muscles with incomplete mouth opening. There
was also rigidity and dystonic posturing of the left arm with
mild distal weakness; jerks that were elicited by taps on
nose, jaw, forehead, crown and neck and that consisted of
bilateral shoulder abduction and forearm flexion with addi-
tional posturing of the face. Following symptomatic treat-
ment with medications, most brainstem abnormalities
gradually ceased. However, the hyperekplexia persisted for
10 years. The timecourse and characteristics of the patient’s
symptoms were interpreted as a possible case of self-
limiting brainstem neuroinflammation (van de Warrenburg
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et al. 2007). The authors also suspected that the neuroin-
flammation was autoimmune-mediated.
The movement disorder symptoms of the above patient
have important similarities to certain cases reported by Sims
et al. (2012) (see Movies S3 (fixed dystonia that remits) and
S4 (paroxysmal dystonic attacks) in this paper). These cases,
as well as the specific pattern of progression of symptoms in
the above case of idiopathic symptomatic hyperekplexia,
may involve migration of neuroinflammation from sites of
peripheral nerve injury into the brainstem. The specific
symptoms suggest that the trigeminal nerve may be in-
volved. Several papers have documented the onset of cranial
dystonias following dental procedures or other trauma to
tissues in the oral cavity (Sankhla et al. 1998; Schrag et al.
1999). Migration of neuroinflammation from an injured
branch of the trigeminal nerve into first-order and second-
order synapses located in the brainstem might serve as
drivers for the genesis of such movement disorders (Sims
et al. 2012).
Brainstem neuroinflammation was previously considered
to explain a case of hyperekplexia, apparently starting from
an insect bite on the lower right leg (Kellett et al. 1998). In
this patient, movement disorders involving the right leg
occurred before generalized body spasms. Migration of
neuroinflammation from the spinal level to the reticular
formation might provide a mechanism to explain the chro-
nicity and progression of these symptoms. Kellett et al. 1998
postulated a pathology involving glycinergic synapses in the
brainstem. A collapse of transmembrane chloride gradients
in post-synaptic neurons (Cooper and Przebinda 2011),
resulting from neuroinflammation in the brainstem, might
account for a loss of glycinergic tone and GABAergic
inhibitory tone (Fig. 2c), possibility producing symptomatic
hyperekplexia.
Ascending and descending neuroinflammation
As discussed earlier, the formation of neuroinflammatory
tracks, as well as a concomitant the loss of inhibitory synapses
and/or interneurons, may allow certain neural pathways to
become sensitized centrally. Post-traumatic dystonias and
CRPS dystonias might evolve in this manner (Cooper
2011a). Neuroinflammation spreading to second-order syn-
apses in supraspinal centers provides a potent mechanism to
destabilize feedback circuits, such as those involved in pro-
prioception, nociception, and autonomic functions. Prolonged
sensitivity may result from the loss of inhibitory tone in the
affected neural pathway (Rossi et al. 2012).
Remote neuroimmune activation could establish secondary
foci of neuroinflammation in the motor cortex (Cooper
2011a), reticular formation, red nucleus, thalamus, cerebel-
lum, rostral ventrolateral medulla (RVM), periaqueductal grey
(PAG). Once inhibitory tone is diminished in two or more
locations, decompensation is likely to occur, leading to exces-
sive gain in both feedforward and feedback neural circuits
(Prescott et al. 2006; Cooper and Przebinda 2011).
In addition to excessive gain in nociceptive, autonomic,
and motor circuits, timing errors could also occur in these
pathways. Loss of inhibitory tone at the cellular level could
easily lead to abnormal time-to-fire behaviors in proprio-
ceptive neurons. This could lead to errors in limb percep-
tion, as well as the regulation of postural tone. Body schema
distortions might also be generated by neuronal coding
problems. We suggest here that neuroinflammatory tracks
may be especially potent in producing information process-
ing errors. In feedback systems, two interacting sites within
the neuraxis, each with neuroinflammation, may be unable
to compensate for corrupted information produced in the
other site. Neuroinflammation driven abnormalities in neuro-
nal firing and timing could potentially result in a host of
symptoms, which are now being termed functional sensory
and motor disorders, instead of psychogenic disorders
(Edwards et al. 2012). Such functional sensorimotor integra-
tion dysfunctions are prevalent, and sometimes extreme, in
CRPS patients (Schwenkreis et al. 2005; McCabe and Blake
2007; Lewis et al. 2007; Turton et al. 2007; McCabe et al.
2009; Huge et al. 2011; Cohen et al. 2012). How specific
symptoms are viewed and labeled can dramatically influence
the course of medical inquiry, patient-practitioner (biosocial)
relationships, as well as the patient acceptance of treatment
plans (Stone and Edwards 2011; Edwards and Bhatia 2012).
Changes in muscular tone, ranging from paresis to fixed
dystonia, may occur in an affected extremity of CRPS patients
(Birklein et al. 2000; van Hilten 2010). Such changes have
long been viewed as stigmata for “hysteria”, psychosomatic,
or psychogenic illness. The dystonias of CRPS and other fixed
posttraumatic dystonias need to be reanalyzed from the stand-
point of neuroinflammation states. Multi-site information cod-
ing failures could easily occur in neural circuits affected by
multi-focal neuroinflammation. Substantial evidence has been
obtained that spinal reflex circuits are disinhibited at the spinal
level in CRPS dystonia (Schouten et al. 2003; van de Beek et
al. 2002). Loss of chloride-dependent inhibitory tone at the
spinal level, resulting from neuroinflammation, could account
for some of this disinhibition. We suggest here that an addi-
tional loss of inhibitory tone at supraspinal sites, such as the
motor cortex (Cooper 2011a; Fig. 3), reticular formation, and/
or red nucleus, might be needed to maximally decompensate
spinal motor reflex circuits, and produce fixed dystonia (Coo-
per MS (2011b).
Whether neuroinflammation spreads from spinal sites to
supraspinal sites in CRPS patients is currently unknown.
However, if neuroinflammation does spread from the spinal
level to supraspinal sites in CRPS patients, disinhibition of
excitatory neurons could occur at both levels, leading to
tonic activation of motor neurons (e.g. Fig. 3). This could
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potentially produce tremor, myoclonus, or fixed dystonia,
depending upon the dynamics and interactions of different
motor control centers. Diminished intracortical inhibition
has been detected in individuals with posttraumatic fixed
dystonias (Espay et al. 2006).
Entrapped nerves are a known etiology of certain cases of
cervical and focal dystonias (Ross et al. 1995; Charness et
al. 1996; Alafaci et al. 2000; Sun et al. 2009). Neuroinflam-
matory tracks, with both peripheral and central neuroinflam-
matory contributions, may play central roles in mediating
the ontogeny of these peripherally induced dystonias. To test
these hypotheses, it may be soon possible to visualize the
distribution and chronicity of both central and peripheral
neuroinflammation in movement disorder patients, using a
complementary set of emerging neuroimaging methods.
Cytokines and changes within the connectome
Standard neurological examinations are carefully constructed
to detect structural defects within the nervous system (Clark et
al. 2009).When aberrant reflexive or higher-order neurological
behaviors are detected, but cannot be immediately linked to
defined structural defects in the nervous system, the aberrant
symptoms are often classified as functional pathologies. This
distinction, however, is confounded when these pathologies
are linked to neuroinflammatory lesions, because neuroinflam-
mation can simultaneously generate both structural and func-
tional changes within the nervous system. Altered cytokine
production in peripheral tissues, infiltrating leukocytes, and
non-neuronal components of the CNS (glia and endothelial
cells) can each become drivers for such changes (Bayas et al.
2002; Ledeboer et al. 2005; Cao and DeLeo 2008; Milligan
and Watkins 2009).
It is well established that pro-inflammatory cytokine expres-
sion is linked to chronic pain (Milligan andWatkins 2009). Pro-
inflammatory cytokines are also associated with depression,
fatigue, sleep disorders, and executive dysfunction (Barbosa et
al. 2012; Blume et al. 2011; Capuron and Miller 2011; Mondal
et al. 2008). In animal models of neuropathic pain, IL-1β
expression becomes elevated in the brainstem, prefrontal cor-
tex, and hippocampus (Apkarian et al. 2006; Besedovsky and
del Rey 2011; del Rey et al. 2011). Elevation of IL-1β RNA
expression in the hippocampus suggests a direct modulation of
a site that is also involved in depression and anxiety (del Rey et
al. 2011). In addition, it has been reported that an increase in IL-
1β expression occurs in the contralateral hippocampus after
unilateral sciatic nerve injury (Apkarian et al. 2006).
This later result, along with other earlier reports (Banati
et al. 2001; Banati 2002; Roberts et al. 2009), supports the
concept that neuroinflammation can become established in
supraspinal centers after peripheral nerve injury. Spreading
neuroinflammation provides a non-psychogenic etiology to
plausibly explain the progression and chronicity of certain
disease states, as well as the migration of symptoms to
different portions of the body. This mechanistic concept of
spreading neuroinflammation within the CNS needs to be
incorporated into differential diagnosis of neurological and
neuropsychiatric disorders, as well as into the standard use
of the Diagnostic and Statistical Manual for Mental Disorders
(DSM). This would substantially advance the recognition
and diagnosis of neuroinflammatory-mediated functional
disorders within the biomedical community.
Cytokine production is a central part of the overlapping
and interlocking mechanisms that produce neuroinflamma-
tory disorders, including CRPS. Neuroendocrine alterations
and disturbances in the metabolism of monoamines have
Fig. 3 A neuroinflammatory model for the generation of fixed dysto-
nia. Injury to a peripheral nerve results in inflammation of motor
neurons. Neuroinflammation is established in the spinal cord, ipsilat-
eral and segmental to the peripheral nerve injury (Sigel et al. 2007; Lee
et al. 2009). Retrograde migration of neuroinflammation (red arrow)
occurs via corticospinal neurons, leading to a secondary neuroinflam-
mation site in the motor cortex (Cooper 2011a). Loss of chloride-
dependent inhibitory tone (similar to panel 2B) and/or an increase in
excitatory tone in the cortical and spinal neuroinflammatory foci lead
to tonic firing of segmental motor neurons. A neuroinflammation-
mediated loss of intracortical inhibition in the motor cortex may also
be required for the genesis of fixed dystonia. (images modified from
The Inner Man™, Medical Illustrations Company LLC)
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been correlatedwith cytokine-inducedmood and cognitive symp-
toms (Capuron et al. 2002; Dantzer et al. 2008; Doorduin et al.
2009; Krishnadas and Cavanagh 2012; Kullman et al. 2012). In
addition, neuroimaging studies have revealed alterations in spe-
cific brain regions during cytokine treatment (Kullmann et al.
2012; Schneider et al. 2012). These changes could contribute to
the development of fatigue, depression, and cognitive alter-
ations in patients with neuroinflammation (Raedlera 2011;
Schedlowski 2012). In CRPS patients, fatigue, paresis, depres-
sion, anxiety, and cognitive impairments are well documented
(Mitchell 1872; Birklein et al. 2000; Apkarian et al. 2004).
Numerous structural and functional changes take place in
neural networks as a result of altered cytokine expression. To
describe effects of neuroimmune activation in neurological
and neuropsychiatric disorders, it is important to consider
how neuroinflammatory lesions and cytokines affect the con-
nectome, the map of neural connections within the nervous
system (Sepulcre et al. 2012). It is also useful to view this
connectome as being part of a larger neuromatrix (Iannetti and
Mouraux 2010), which is modulated by cellular communica-
tion between with a variety of cellular players, including glia,
endothelial cells, and leukocytes (Milligan and Watkins 2009;
Hughes et al. 2012). Cytokines help mediate these cellular
interactions, and thus modify the activities of multi-partiate
synapses (i.e. synapses betweenmultiple cell types) within the
neuromatrix (De Leo et al. 2006).
At the cellular level, neuroinflammation can produce
structural lesions in the following ways: demyelination of
axonal fibers (Staff et al. 2010); stripping of synapses from
cell bodies by microglia (Perry and O’Connor 2010; Yamada
et al. 2011); autoimmune attack on specific interneurons
(Rokocevic and Floeter 2012); sprouting of afferent axonal
terminals; dieback of sensory nerve endings (Oaklander and
Fields 2009); altered dendritic aborizations (Jakubs et al.
2008). These microscopic structural lesions lead to functional
changes of local neuronal circuits. Although these structural
changes within the connectome may remain largely undetect-
able using clinical neuroimaging methods, the functional/
behavioral changes that result from these structural changes
can be profound. For instance, small fiber neuropathies in the
cornea are correlated with the occurrence of painful blephar-
opasm (Borsook and Rosenthal 2011). In an experimental
study, large-fiber neuropathies in peripheral nerves have been
correlated with the onset of fixed dystonic postures (Siegel et
al. 2007). Clinically, peripheral nerve injury is a known
antecedent for many forms of dystonia (Jankovic 2001;
2009), including the fixed dystonias seen in CRPS II patients
(50% of the cohort) (Birklein et al. 2000).
In the CNS, activated microglia can strip neuronal cell
bodies of synapses and dendrites, as well as promote demye-
lination (Perry and O’Connor 2010; Yamada et al. 2011).
These microstructural lesions might help to explain the per-
sistent changes in pain processing in children with a history of
CRPS, months after their allodynia has remitted (Lebel et al.
2008). In post-surgical inflammatory neuropathies, reversible
demyelination can occur (Staff et al. 2010). Weakness and
pain disappear in the affected extremities as remyelination
proceeds. The cellular behaviors that underlie demyelination
and remyelination should be considered when dealing with
the transient expression of neurological and neuropsychiatric
symptoms, as well as their long-term remission.
From a number of neuroautoimmune disorders, it is
known that the pathological ramifications of neuroautoanti-
bodies entering the parenchyma of the nervous system can
be profound. Autoantibodies to β2AR in CRPS patients, for
instance, could bind to β2AR receptors located on microglia
(Mantyh et al. 1995; Wang et al. 2010), leading to autoim-
mune attack on these neuroimmune cells, as well as specific
types of neurons and astrocytes, which also express β2AR.
Aberrant cytokine production from activated microglia is
likely to occur if these neuroimmune cells are subjected to
an autoimmune attack mediated by autoantibodies and in-
filtrating leukocytes.
CRPS patient have elevated levels of the pro-inflammatory
cytokines IL-1β and IL-6 in their cerebrospinal fluid, as well
as reduced levels of the anti-inflammatory cytokines IL-4 and
IL-10 (Alexander et al. 2005; Alexander et al. 2005). In
peripheral tissues, pro-inflammatory cytokines are found in
the affected limbs of CRPS patients (Schinkel et al. 2006), and
are enhanced upon transcutaneous electrical stimulation, indi-
cating that neurogenic inflammation is present (Birklein and
Schmelz 2008). In general, it is known that antidromic firing
of C-fibers (driven by both axonal reflex and dorsal root
reflex) can result is CGRP (calcitonin gene related peptide)
and SP (substance P) release from the peripheral endings of C-
fibers (Willis 1999; Hagains et al. 2010). CGRP and SP
sensitize mast cells and the endings of C-fibers. At the periph-
eral level, local cytokine production can also drive the pro-
gression of neuroinflammatory pathologies in many target
organs (Li et al. 2009b; Lia et al. 2009). MicroRNA levels
are also altered in the blood of CRPS patients (Orlova et al.
2011). These miRNA biomarkers potentially offer a new way
for monitoring inflammation in CRPS patients, as well as
stratifying patients for therapeutic interventions.
A number of CRPS co-morbidities, including visceral
pain, osteopenia, edema, and rashes and ulcerations of the
skin, may involve prolonged neurogenic inflammation, as
well as its pathological consequences (Oaklander and Fields
2009). Through its corruption of circuit logic within the
connectome (Cervero and Laird 1996; Prescott et al. 2006;
Cooper and Przebinda 2011), neuroinflammation in spinal,
supraspinal, and autonomic centers, might also generate un-
usual modulations of these diverse pathologies (e.g. episodic
or diurnal expression of symptoms). However idiosyncratic
the presentation of symptoms may be in individual CRPS
patients, it is increasingly difficult to assert a purely
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psychogenic etiology for the co-morbidities of CRPS. The
structural and functional consequences of neuroinflammatory
lesions provide a logical framework for conceptual modeling
and clinical investigation, during the differential diagnosis of
unusual neurological or neuropsychiatric symptoms.
Promising neuroimaging approaches
A MRI-based method that may eventually provide a means to
diagnose neuroinflammation is magnetic resonance spectros-
copy (MRS). 1H-MRS measures small changes in proton
resonance that result from shielding by orbiting electrons.
Depending on the chemical structure of the substance being
measured, its resonance signature may be detected, and its
amplitude (i.e. concentration) can be quantified.
Using this method, a variety of neurochemicals can be
identified, including various neurotransmitters and their
byproducts (glutamate, glutamine and GABA) membrane
components (myo-inositol) constituents of metabolic path-
ways (choline and creatine) and others with no well under-
stood purpose, but that are sensitive to neuronal function
and damage (n- acetyl aspartate, abbreviated as NAA). MRS
has been used in a variety of studies to examine chemical
changes related to disease processes that may involve neuro-
inflammation (Holt et al. 2012).
Aside from 1H-MRS, hyperpolarized 13C-MRS provides
a means to label carbon atoms in specific metabolically
active molecules, which can be injected and are taken up
into physiological processes in the body (Rothman et al.
2002). While not radioactive, 13C can produce an NMR
signal that is small, but detectable. The imaging advantage
of 13C is being able to focus on specific metabolic path-
ways, such as GABA and glutamate, and the ability to
quantify their concentrations and changes in concentration
as other variables are manipulated. These methods have
been used pre-clinically to detect tumors and tumor metab-
olism. Hyperpolarized 13C-MRS has yet to be utilized to
image neuroinflammation in human patients.
As physical properties of the CNS change with neuro-
inflammation, it might be possible to visualize them using
non-invasive imaging methods that depend only on intrinsic
properties of the CNS. Using methods such as MRI, the
difficulty is often not in the degree of sensitivity, but in
specificity. Especially in the case of MRI, the measures that
can be obtained are affected by a large variety of factors, and
so may differ from the population mean due to a variety of
reasons, many of which may reflect properties not involved
in the disease process. The specific causes of changes found
in MRI data from the CNS can be difficult to infer. Changes
in the number or size and type of any CNS cell could
contribute to these structural changes, including the size
and numbers of either different classes of neurons or glia,
as well as their metabolic state (Shan and Pan 2007).
While intriguing, such effects are also often inconclusive
as to their mechanisms. Additionally, due to a high degree of
individual variability, many imaging protocols require that
data be obtained before and after the eliciting event or some
intrinsic change in the CNS, which provides a much more
sensitive basis to detect effects compared with what is
essentially a between-subjects comparison that is found in
most physician offices. These two features: (a) lack of
specificity and (b) lack of sensitivity for a single imaging
sample in an individual patient, remain major barriers to
using imaging to identify neuroinflammatory lesions in
clinical practice. What is needed is to identify measures that
are both sensitive and specific, and can be obtained from a
single imaging session.
Recently, magnetic nanoparticles have been used in human
patients to detect the infiltration of leukocytes into injured
nervous tissues (Stoll and Bendszus 2010; Thorek et al.
2011; Deddens et al. 2012). New contrast agents are being
developed for PET/SPECT (Chopra et al. 2012), MRI (Stoll et
al. 2012), and MRS imaging (Li et al. 2009a; Witney and
Brindle 2010) as well. MRS and diffusion tensor imaging
(DTI) can also be used to examine changes in nervous tissues
affected by factors such as chronic viral infection (Holt et al.
2012). These rapidly advancing technological developments
may also allow neuroinflammation to be imaged in difficult
sites, such as the brainstem and spinal cord. Such neuroimag-
ing studies would be hugely beneficial for understanding the
establishment and spread of CRPS symptoms.
Conclusion
In clinical practice, when an organic explanation cannot
be found for functional disorders, psychogenic etiologies
are often asserted. However, as the understanding of
functional disorders improves, it appears that neuroim-
mune and neuroinflammatory disorders are much more
common than previously thought. Neuroautoimmunity
combined with neuroinflammation together provide a via-
ble etiology for the relapsing-remitting chronicity, atypical
presentation and intensity of neurological and psychiatric
symptoms.
When faced with medically unexplained symptoms,
health practitioners and patients should actively seek phys-
iological hypotheses, as an alternative to diagnoses of soma-
toform or conversion disorders. Neuroinflammatory lesions,
along with their functional consequences, should always
be considered in the differential diagnosis of medically
unexplained symptoms, even when commonly used clini-
cal neuroimaging protocols fail to reveal positive evidence of
neuroinflammation.
When viewing the symptoms of an individual patient,
health practitioners should anticipate that a given patient
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might have a complex, multifocal pattern of neuroinflam-
mation and associated functional symptoms. The presenta-
tion of symptoms may be idiosyncratic to that patient,
depending on the topographic pattern and severity of neuro-
inflammation and other variables, often yet undiscovered.
However, key mechanistic elements of spreading neuroin-
flammation could be common to a wide spectrum of patients
and disorders. By integrating neuroinflammation and neuro-
autoimmune concepts into the differential diagnosis of neu-
rological and neuropsychiatric symptoms, a number of
functional sensory and motor disorders may become less
medically unexplainable than was previously thought. As
diagnostic methods continue to improve, it may someday be
possible for neuroautoimmuity and neuroinflammation to be
commonly assessed as a part of a differential diagnosis of
chronic pain syndromes such as CRPS.
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